Terms: = Brain cancer AND ERCC2, TTD, 2068, ENSG00000104884, COFS2, P18074, MGC102762, XPD, MGC126219, MGC126218, EM9 AND Prognosis
9 results:
1. DMC-siercc2 hybrid nanoparticle enhances TRAIL sensitivity by inducing cell cycle arrest for glioblastoma treatment.
Song M; Wang T; Liu T; Lei T; Teng X; Peng Q; Zhu Q; Chen F; Zhao G; Li K; Qi L
Biomed Pharmacother; 2024 May; 174():116470. PubMed ID: 38565061
[TBL] [Abstract] [Full Text] [Related]
2. The XRCC1 and TP53 gene polymorphisms are associated with advanced-stage disease and early distant metastasis at diagnosis in non-small cell lung cancer.
Karaağaç M; Geredeli Ç; Yıldırım MS; Altınok T; Dede İ; İnal A; Zamani AG; Kaya B; Demirkazık A; Artaç M
J Cancer Res Ther; 2023; 19(5):1248-1254. PubMed ID: 37787291
[TBL] [Abstract] [Full Text] [Related]
3. Real-World Evaluation of the Management, Treatment Pathways and Outcome of Melanoma Patients with Target Therapies in Italy.
Marcon IG; Valsecchi D; Durso L; Premoli E; Sangiorgi D; Perrone V; Catena L; Degli Esposti L
Adv Ther; 2023 Sep; 40(9):3875-3895. PubMed ID: 37368101
[TBL] [Abstract] [Full Text] [Related]
4. Inhibition of DNA-repair genes Ercc1 and Mgmt enhances temozolomide efficacy in gliomas treatment: a pre-clinical study.
Boccard SG; Marand SV; Geraci S; Pycroft L; Berger FR; Pelletier LA
Oncotarget; 2015 Oct; 6(30):29456-68. PubMed ID: 26336131
[TBL] [Abstract] [Full Text] [Related]
5. DNA repair gene ERCC1 and xpd polymorphisms predict glioma susceptibility and prognosis.
Chen DQ; Yao DX; Zhao HY; Yang SJ
Asian Pac J Cancer Prev; 2012; 13(6):2791-4. PubMed ID: 22938460
[TBL] [Abstract] [Full Text] [Related]
6. [Comparison of MGMT and ERCC₂ expression in temozolomide for the treatment of malignant glioma drug resistance and their genetic relationship].
Hou X; Zhao Y; Zheng YR; Wang JJ; Wu ZC; Sun JH
Zhonghua Yi Xue Za Zhi; 2011 Jan; 91(1):56-8. PubMed ID: 21418965
[TBL] [Abstract] [Full Text] [Related]
7. Expression analyses of 27 DNA repair genes in astrocytoma by TaqMan low-density array.
Jiang Z; Hu J; Li X; Jiang Y; Zhou W; Lu D
Neurosci Lett; 2006 Dec; 409(2):112-7. PubMed ID: 17034947
[TBL] [Abstract] [Full Text] [Related]
8. 1H-MRS in vivo predicts the early treatment outcome of postoperative radiotherapy for malignant gliomas.
Tarnawski R; Sokol M; Pieniazek P; Maciejewski B; Walecki J; Miszczyk L; Krupska T
Int J Radiat Oncol Biol Phys; 2002 Apr; 52(5):1271-6. PubMed ID: 11955739
[TBL] [Abstract] [Full Text] [Related]
9. The costs of managing patients with malignant glioma at a neuro-oncology clinic.
Latif AZ; Signorini D; Gregor A; Whittle IR
Br J Neurosurg; 1998 Apr; 12(2):118-22. PubMed ID: 11013662
[TBL] [Abstract] [Full Text] [Related]
